Streetbeat News

Products Services

ALVO

Alvotech has received approval from the Egyptian Drug Authority to manufacture and distribute AVT02 (Adalimumab), a biosimilar for Humira, under the name Adalimumab-EVA. This drug is indicated for rheumatoid arthritis and several other inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 9:02 am

HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the approval of Roche's Tecentriq SC, which uses Halozyme's ENHANZE drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain. The technology allows for subcutaneous delivery, reducing the delivery time from 30-60 minutes to approximately seven minutes. The drug will be available for certain types of lung, bladder, breast, and liver cancer.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 8:53 am

AAPL

SSNLF

Apple Inc. (NASDAQ:AAPL) is expected to take the lead over Samsung Electronics (OTC:SSNLF) in the smartphone market with its upcoming iPhone 15's design. The new model is rumored to have a front display with incredibly thin bezels, measuring just 1.55 mm, which could make it the world's thinnest smartphone bezel. This is a significant shift from Apple's previous designs, which had larger borders around the screen. The iPhone 15 lineup is expected to launch on September 12.

Portfolio Pulse from Ananya Gairola

August 29, 2023 | 8:37 am

AAPL

SSNLF

Apple Inc.'s iPhones accounted for four out of the top five shipped smartphones globally in the first half of 2023, according to data from research firm Omdia. Samsung Electronics Co Ltd.’s Galaxy A14 was the only non-iPhone smartphone in the top five. Despite concerns of a global economic slowdown, Apple managed to increase its shipments to 86.4 million, up from last year's 83.2 million. Apple's share in the top ten smartphone shipments increased to nearly 65% in the first half of 2023 from 59% in the same period last year.

Portfolio Pulse from Rounak Jain

August 29, 2023 | 8:18 am

TSLA

Elon Musk has announced plans to integrate the rebranded Twitter, now known as X, into Tesla vehicles. This has sparked both excitement and concern, with safety advocates raising questions about the potential for distracted driving. The announcement came in response to a Tesla user's query about watching X videos on a Tesla. While some users welcomed the idea, others expressed concerns about the potential for accidents due to distraction.

Portfolio Pulse from Ananya Gairola

August 29, 2023 | 7:55 am

AAPL

TSLA

Tesla CEO Elon Musk compared the company's software to Apple's, stating that it cannot be simply copied due to the unique hardware requirements. Musk acknowledged that Chinese EV makers like XPeng, Li Auto, and Nio are learning from Tesla and possibly incorporating the lessons into their own ADAS software.

Portfolio Pulse from Anan Ashraf

August 29, 2023 | 7:25 am

VSAT

Viasat, Inc. (NASDAQ:VSAT) has been selected as the inflight connectivity provider for Korean Air's upcoming fleet of Airbus A321neo aircraft. Korean Air will receive a total of 30 Airbus A321neos by 2027, all of which will be delivered with Viasat's connectivity solution.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 7:19 am

VALN

Valneva's Chikungunya vaccine has entered regulatory review after Health Canada accepted its license application. This is a significant step towards the vaccine's approval and distribution in Canada.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:35 am

GOOGL

NVDA

XLK

CNBC Mad Money host Jim Cramer has picked Alphabet, Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) and Nvidia Corp. (NASDAQ:NVDA) as his top mega-cap tech stocks, stating that both are ready to run. Alphabet's NFL Sunday Ticket deal and Nvidia's strong Q2 results and upbeat outlook are seen as key drivers. The Technology Select Sector SPDR Fund (NYSE:XLK) also rose 0.82% to $170.09.

Portfolio Pulse from Shanthi Rexaline

August 29, 2023 | 6:35 am

RHHBF

RHHBY

RHHVF

Roche's drug Evrysdi has received approval from the European Commission for the treatment of babies under two months old with Spinal Muscular Atrophy. This approval could potentially increase Roche's market share in the European pharmaceutical market.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:25 am